WEG232 is a topical treatment with specific substance P-receptor inhibitor for Erlotinib-induced facial dermatitis and hair loss in cancer patients [16-June-2020] NEW YORK , June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington U
| NEW YORK, June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.
The company has increased its commitment to further the science behind this therapeutic with Dr. William Wegliki’s lab at GW. Hoth intends to request a Pre-IND meeting with the FDA by year-end. Hoth continues to develop topical WEG232 formulation for treatment of mild to moderate (grades 1-3) rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. A recent research study suggested the topical application of WEG232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity. Future studies will include:
“We are pleased to broaden our relationship with the George Washington University as we continue to make great strides in bringing a much needed therapeutic to patients struggling with the many side effects of chemo and immunotherapy,” stated Mr. Robb Knie, CEO of Hoth Therapeutics. About Hoth Therapeutics, Inc. Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com. Forward-Looking Statement Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Investor Contact: KCSA Strategic Communications
SOURCE Hoth Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:HOTH |
View original content to download multimedia:
